NCT01614821View on ClinicalTrials.gov

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 9, 2016

Study Completion Date

September 15, 2018

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

PCI-32765

Taken orally, once daily in the morning

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

94305

Stanford University, Palo Alto

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01614821 - Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter